Clinical trial
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in…
NCT00078949 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00078949 |
|---|---|
| Title | Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma |
| Official title | Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell… |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cisplatin, cytarabine, dexamethasone, gemcitabine hydrochloride |
| Enrollment | 849 |
| Start date | Aug 27, 2003 |
| Primary completion | Jul 29, 2013 |
| Completion | Dec 1, 2018 |
| First posted | Mar 9, 2004 |
| Last update posted | Aug 23, 2023 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: